CA2656016C - Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques - Google Patents
Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques Download PDFInfo
- Publication number
- CA2656016C CA2656016C CA2656016A CA2656016A CA2656016C CA 2656016 C CA2656016 C CA 2656016C CA 2656016 A CA2656016 A CA 2656016A CA 2656016 A CA2656016 A CA 2656016A CA 2656016 C CA2656016 C CA 2656016C
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- pressure
- foot
- areas
- hyperspectral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000008960 Diabetic foot Diseases 0.000 title abstract description 32
- 238000005516 engineering process Methods 0.000 title description 30
- 208000026062 Tissue disease Diseases 0.000 title description 2
- 208000025865 Ulcer Diseases 0.000 claims abstract description 130
- 230000036269 ulceration Effects 0.000 claims abstract description 40
- 238000000701 chemical imaging Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims description 103
- 231100000397 ulcer Toxicity 0.000 claims description 89
- 230000000287 tissue oxygenation Effects 0.000 claims description 62
- 238000006213 oxygenation reaction Methods 0.000 claims description 42
- 230000035790 physiological processes and functions Effects 0.000 claims description 33
- 208000027418 Wounds and injury Diseases 0.000 claims description 30
- 206010052428 Wound Diseases 0.000 claims description 27
- 208000028867 ischemia Diseases 0.000 claims description 27
- 108010064719 Oxyhemoglobins Proteins 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 26
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims description 23
- 108010002255 deoxyhemoglobin Proteins 0.000 claims description 23
- 208000003790 Foot Ulcer Diseases 0.000 claims description 20
- 230000015556 catabolic process Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 230000006835 compression Effects 0.000 claims description 12
- 238000007906 compression Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 201000002282 venous insufficiency Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 238000004590 computer program Methods 0.000 claims 12
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 85
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 76
- 239000001301 oxygen Substances 0.000 abstract description 76
- 229910052760 oxygen Inorganic materials 0.000 abstract description 76
- 230000010412 perfusion Effects 0.000 abstract description 65
- 238000012384 transportation and delivery Methods 0.000 abstract description 23
- 238000002266 amputation Methods 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 21
- 238000000605 extraction Methods 0.000 abstract description 18
- 238000003384 imaging method Methods 0.000 abstract description 14
- 230000004060 metabolic process Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 12
- 238000001931 thermography Methods 0.000 abstract description 4
- 238000009556 duplex ultrasonography Methods 0.000 abstract description 2
- 210000000746 body region Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 253
- 210000002683 foot Anatomy 0.000 description 166
- 238000005259 measurement Methods 0.000 description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 60
- 201000010099 disease Diseases 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 44
- 238000013507 mapping Methods 0.000 description 35
- 230000035876 healing Effects 0.000 description 31
- 239000003814 drug Substances 0.000 description 25
- 210000003414 extremity Anatomy 0.000 description 21
- 238000001228 spectrum Methods 0.000 description 21
- 230000035882 stress Effects 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 238000004611 spectroscopical analysis Methods 0.000 description 20
- 230000002792 vascular Effects 0.000 description 20
- 108010054147 Hemoglobins Proteins 0.000 description 19
- 102000001554 Hemoglobins Human genes 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 19
- 230000002981 neuropathic effect Effects 0.000 description 19
- 206010022562 Intermittent claudication Diseases 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 208000024980 claudication Diseases 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 16
- 210000000245 forearm Anatomy 0.000 description 16
- 230000009885 systemic effect Effects 0.000 description 16
- 208000018262 Peripheral vascular disease Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 14
- 201000001119 neuropathy Diseases 0.000 description 14
- 230000007823 neuropathy Effects 0.000 description 14
- 208000033808 peripheral neuropathy Diseases 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 230000003595 spectral effect Effects 0.000 description 13
- 238000009530 blood pressure measurement Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 210000003141 lower extremity Anatomy 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000004089 microcirculation Effects 0.000 description 11
- 230000024883 vasodilation Effects 0.000 description 11
- 206010047141 Vasodilatation Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 208000000558 Varicose Ulcer Diseases 0.000 description 9
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 229960002460 nitroprusside Drugs 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000004210 Pressure Ulcer Diseases 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000035901 Ischaemic ulcer Diseases 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 230000035479 physiological effects, processes and functions Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 206010040943 Skin Ulcer Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 210000003423 ankle Anatomy 0.000 description 6
- 210000001142 back Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 210000002414 leg Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000000250 revascularization Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000451 tissue damage Effects 0.000 description 6
- 231100000827 tissue damage Toxicity 0.000 description 6
- 229940124549 vasodilator Drugs 0.000 description 6
- 239000003071 vasodilator agent Substances 0.000 description 6
- 206010011985 Decubitus ulcer Diseases 0.000 description 5
- 206010056340 Diabetic ulcer Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000001804 debridement Methods 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 206010062542 Arterial insufficiency Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000014770 Foot disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 206010049771 Shock haemorrhagic Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000007310 pathophysiology Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 206010054805 Macroangiopathy Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010031252 Osteomyelitis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 3
- 229960004266 acetylcholine chloride Drugs 0.000 description 3
- 210000003447 amputation stump Anatomy 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- -1 frequent urination Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004895 regional blood flow Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 208000037997 venous disease Diseases 0.000 description 3
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001505 Musculoskeletal Abnormalities Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010057178 Osteoarthropathies Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008721 basement membrane thickening Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000011542 limb amputation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000012306 spectroscopic technique Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010071050 Ankle deformity Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000036376 Femoral artery occlusion Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000447437 Gerreidae Species 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010063900 Steal syndrome Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000452 mid-foot Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000008399 response to wounding Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000398 surgical flap Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
Cette invention concerne d'une manière générale une carte-index comprenant des informations à la fois de pression et de perfusion relatives au pied d'un patient diabétique à des fins de traitement. La carte-index peut également être une carte de perfusion et/ou métabolisme des tissus (reflétant l'apport d'oxygène et l'extraction d'oxygène) obtenue par imagerie thermique, imagerie hyperspectrale ou par balayage par ultrasons duplex, angiographie par résonance magnétique (ARM), tomographie par ordinateur (CT) ou imagerie Doppler à laser. Ces informations contribuent au traitement en prévention de l'ulcération et de l'amputation du pied diabétique et au traitement de tissus touchés en prévention de la perte de tissus dans d'autre régions du corps.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70942205P | 2005-08-19 | 2005-08-19 | |
| US60/709,422 | 2005-08-19 | ||
| US78597706P | 2006-03-27 | 2006-03-27 | |
| US60/785,977 | 2006-03-27 | ||
| US11/396,941 US8374682B2 (en) | 2005-04-04 | 2006-04-04 | Hyperspectral imaging in diabetes and peripheral vascular disease |
| US11/396,941 | 2006-04-04 | ||
| PCT/US2006/032593 WO2007022508A2 (fr) | 2005-08-19 | 2006-08-21 | Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2656016A1 CA2656016A1 (fr) | 2007-02-22 |
| CA2656016C true CA2656016C (fr) | 2017-05-16 |
Family
ID=40515038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2656016A Expired - Fee Related CA2656016C (fr) | 2005-08-19 | 2006-08-21 | Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2656016C (fr) |
-
2006
- 2006-08-21 CA CA2656016A patent/CA2656016C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2656016A1 (fr) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190059787A1 (en) | Hyperspectral technology for assessing and treating diabetic foot and tissue disease | |
| US8548570B2 (en) | Hyperspectral imaging of angiogenesis | |
| CA2947613C (fr) | Imagerie hyperspectrale mise en oeuvre chez des patients souffrant de diabete ou d'une maladie vasculaire peripherique | |
| Lung et al. | Emerging technologies for the prevention and management of diabetic foot ulcers | |
| US8224425B2 (en) | Hyperspectral imaging in diabetes and peripheral vascular disease | |
| EP3573521B1 (fr) | Système pour évaluer des complications diabétiques du système circulatoire | |
| Mateus et al. | Photoplethysmography for non-invasive in vivo measurement of bone hemodynamics | |
| WO2017139796A1 (fr) | Procédé et appareil pour l'évaluation de la santé vasculaire tissulaire | |
| López-Moral et al. | A comparison of hyperspectral imaging with routine vascular noninvasive techniques to assess the healing prognosis in patients with diabetic foot ulcers | |
| WO2007022508A2 (fr) | Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques | |
| Leiva et al. | Breath-hold paradigm to assess variations in oxygen flow in diabetic foot ulcers using a noncontact near-infrared optical scanner | |
| CA2656016C (fr) | Technologie hyperspectrale permettant d'evaluer et de traiter la maladie des tissus et du pied diabetiques | |
| Bartolo et al. | The effect of induced joint restriction on plantar pressure during gait–a pilot study | |
| Nardi et al. | Nicola Lamberti1, Fabio Manfredini1, 2, Mirko Tessari3, Erica Menegatti3, 4 | |
| Saiko et al. | Optical Methods for Managing the Diabetic Foot | |
| Schleicher et al. | Application of NIR spectroscopy in the assessment of diabetic foot disorders | |
| Chao | An innovative assessment of the biomechanical properties of plantar tissues and diabetic foot ulcers | |
| Zhang et al. | Dynamic Microcirculation Characteristics of Plantar Skin Under Metatarsal Head of Human Foot in Response to Life‐Like Pressure Stimulus | |
| Schwab | Quantifying contact force artefact in near infrared spectroscopy | |
| Meloy | Analysis of the relationship between sacral skin blood flow and transcutaneous oxygenation in response to causative factors of pressure ulcers in healthy subjects | |
| Han et al. | Management of chronic wounds: with focus on diabetic ulcers | |
| Purewal et al. | Clinical assessment of neuropathy, vascular disease and the leg in diabetes | |
| Knight | Non-invasive techniques for predicting soft tissue during pressure induced ishaemia. | |
| Yudovsky | Spectroscopy of Multilayered Biological Tissues for Diabetes Care | |
| Tisdall | Transcutaneous Oximetry (tcpO2) A study to Evaluate the Clinical Role of tcpO2 in the Vascular Patient Cohort and in Particular Those Patients with Foot Ulceration. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220822 |